EUVIMEDEUVIMED entdecken
Leitlinie

EuroGuiderm guideline on lichen sclerosus—Treatment of lichen sclerosus

G Kirtschig iD, M Kinberger iD, A Kreuter, R Simpson, A Günthert, C van Hees, K Becker, M J Ramakers, M Corazza, S Müller iD, S von Seitzberg, M J Boffa und 25 weitere

Journal of the European Academy of Dermatology and Venereology · 2024-10 · 38 (10) · 1874-1909

DOI: 10.1111/jdv.20083 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024-06. Verfasst von G Kirtschig und 36 weiteren Autor:innen. Beteiligte Einrichtung: Medbase Health Centre, Frauenfeld, Switzerland. Hauptthemen laut MEDLINE: Lichen Sclerosus et Atrophicus. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 279 Literaturangaben. Gefördert von: EuroGuiDerm Centre for Guideline Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Lichen sclerosus (LS) is an inflammatory skin disease affecting all ages. LS typically involves the anogenital site where it causes itching and soreness; it may lead to sexual and urinary dysfunction in females and males; however, it may be asymptomatic. First signs of LS are usually a whitening of the genital skin, sometimes preceded by redness and oedema; fissuring, scarring, shrinkage and fusion of structures may follow in its course. LS is associated with an increased risk of genital cancer. LS has a huge impact on the quality of life of affected patients, and it is important to raise more awareness of this not uncommon disease in order to diagnose and treat it early.

Objectives

The guideline intends to provide guidance on the diagnostic of LS (part 1), highlight important aspects in the care of LS patients, generate recommendations and treatment algorithms (part 2) on topical, interventional and surgical therapy, based on the latest evidence, provide guidance in the management of LS patients during pregnancy, provide guidance for the follow‐up of patients with LS and inform about new developments and potential research aspects. Materials and Methods The guideline was developed in accordance with the EuroGuiDerm Methods Manual v1.3 https://www.edf.one/de/home/Guidelines/EDF‐EuroGuiDerm.html . The wording of the recommendations was standardized (as suggested by the GRADE Working Group). The guideline development group is comprised of 34 experts from 16 countries, including 5 patient representatives.

Results

Ultrapotent or potent topical corticosteroids in females and males, adults and children remain gold standard of care for genital LS; co‐treatment with emollients is recommended. If standard treatment fails in males, a surgical intervention is recommended, complete circumcision may cure LS in males. UV light treatment is recommended for extragenital LS; however, there is limited scientific evidence. Topical calcineurin inhibitors are second line treatment. Laser treatment, using various wave lengths, is under investigation, and it can currently not be recommended for the treatment of LS. Treatment with biologics is only reported in single cases.

Conclusions

LS has to be diagnosed and treated as early as possible in order to minimize sequelae like scarring and cancer development. Topical potent and ultrapotent corticosteroids are the gold standard of care; genital LS is often a lifelong disease and needs to be treated long‐term.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lichen Sclerosus et AtrophicusHumansFemaleMalePregnancyLaser TherapyPregnancy Complications

Autor:innen und Institutionen

  • Medbase Health Centre, Frauenfeld, Switzerland.
  • Division of Evidence-Based Medicine (dEBM), Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin,…
  • Department of Dermatology, Venereology, and Allergology, HELIOS St. Elisabeth Hospital Oberhausen, Oberhausen, Germany.
  • Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
  • Gynäkologisches Tumorzentrum St. Anna, Lucerne, Switzerland.
  • Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

ORCID-Profile: G Kirtschig, M Kinberger, S Müller, C C Chi, J N Dauendorffer, H K Larsen, M Sárdy, A Tsiogka, R N Werner

Förderung

  • EuroGuiDerm Centre for Guideline Development

Zitieren

APA

Kirtschig, G., Kinberger, M., Kreuter, A., Simpson, R., Günthert, A., van Hees, C., Becker, K., Ramakers, M. J., Corazza, M., Müller, S., von Seitzberg, S., Boffa, M. J., Stein, R., Barbagli, G., Chi, C. C., Dauendorffer, J. N., Fischer, B., Gaskins, M., Hiltunen-Back, E., …, & Werner, R. N. (2024). EuroGuiderm guideline on lichen sclerosus—Treatment of lichen sclerosus. Journal of the European Academy of Dermatology and Venereology, 38(10), 1874-1909. https://doi.org/10.1111/jdv.20083

Vancouver

Kirtschig G, Kinberger M, Kreuter A, Simpson R, Günthert A, van Hees C, et al. EuroGuiderm guideline on lichen sclerosus—Treatment of lichen sclerosus. Journal of the European Academy of Dermatology and Venereology. 2024;38(10):1874-1909. doi:10.1111/jdv.20083

BibTeX
@article{Kirtschig2024,
  author = {Kirtschig, G and Kinberger, M and Kreuter, A and Simpson, R and Günthert, A and van Hees, C and Becker, K and Ramakers, M J and Corazza, M and Müller, S and von Seitzberg, S and Boffa, M J and Stein, R and Barbagli, G and Chi, C C and Dauendorffer, J N and Fischer, B and Gaskins, M and Hiltunen-Back, E and Höfinger, A and Köllmann, N H and Kühn, H and Larsen, H K and Lazzeri, M and Mendling, W and Nikkels, A F and Promm, M and Rall, K K and Regauer, S and Sárdy, M and Sepp, N and Thune, T and Tsiogka, A and Vassileva, S and Voswinkel, L and Wölber, L and Werner, R N},
  title = {EuroGuiderm guideline on lichen sclerosus—Treatment of lichen sclerosus},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  volume = {38},
  number = {10},
  pages = {1874--1909},
  doi = {10.1111/jdv.20083}
}
Kostenlos starten →